Lixumistat

N/A

Report date: 2024/04/25 17:31:16
NME

Base Information

Drug NameLixumistat
Drug Alias NameIM-156
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionAMP-activated protein kinases activatorsMitochondrial oxidative phosphorylation inhibitorsAngiogenesis inhibitors
TargetsAMP-activated protein kinases
Therapy Area/IndicationsSolid tumoursIdiopathic Pulmonary FibrosisProstatic Neoplasms, Castration-Resistant +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesSouth Korea
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesImmunomet Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesImmunomet Therapeutics IncNational Cancer InstituteThe University Of Texas MD Anderson Cancer Center
Inactive CompaniesN/A
Active IndicationsIdiopathic Pulmonary FibrosisProstatic Neoplasms, Castration-ResistantPancreatic Neoplasms +[6] 
Inactive IndicationsSolid tumours

Other Information

ATC CodeN/A
Related LinksN/A